US FDA Grants Expanded Approval of ELEVIDYS Gene Therapy for DMD Patients Ages 4 and Above
Join MDA
A place where individuals and families are at the heart of everything we do.
Support the MDA Mission
Give to MDA today and help people living with neuromuscular diseases every day!
Volunteer and Empower Lives
Choose from one of many volunteer opportunities and make a difference for people living with neuromuscular diseases.
Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted comprehensive briefing material and a meeting request to the FDA to discuss the filing of a New Drug Application (NDA) for Raxone® (idebenone) for the treatment of DMD patients not taking concomitant glucocorticoids.